Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.
Abstract
Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.
Overview
CoChat Summary
TL;DR
The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.
Key findings
- In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
- Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
- In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
- qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.
Methods
- Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
- Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
- Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.
Limitations
- The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
- The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
- Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While highly active anti-retroviral therapy (HARRT) has dramatically decreased mortality from HIV-1 infection, there is currently no effective strategy to target the latent form of HIV-1 proviruses 5 .”
What the sources say
- Partly supportedcites [5] Eisele, E. & Siliciano, R. F. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37, 377–388 (2012). sourceExperimental — accuracy not yet measured
The Introduction describes the latent reservoir as a major barrier to HIV-1 eradication. In “The latent reservoir in resting CD4+ T cells,” the paper says reactivation alone may not purge that reservoir, but it also reports that SAHA can perturb it in vivo. Thus, the paper supports the lack of an established strategy to eliminate latent infection, not the categorical claim that no strategy effectively targets it. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fortunately, the CRISPR/Cas9 system has the advantage in size compared with TALENs 22 .”
What the sources say
- Partly supportedcites [22] Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. (2013). sourceExperimental — accuracy not yet measured
The Future directions section says the large size of TALENs may limit delivery by size-restricted vectors. It does not compare TALEN size with CRISPR/Cas9 size, so it supports the TALEN size concern but not the claimed comparative advantage. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Triple TF resulted in a significant decrease in the mean percentage of GFP positive cells from 40.8% to 2.1% ( p = 0.0001) was observed.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we successfully disrupted the expression of HIV-1 provirus utilizing the CRISPR/Cas9 system ( Fig. 1 ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A similar reduction in GFP expression was observed in c5 and c19 cells transfected with the T5 CRISPR/Cas9 system after 5-Aza-dC/TSA treatment ( Fig. 3A and B ).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
23 more claims
Create a free account to see all 48 claims and every source verdict.
- Probably not a substantial claim. 8
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ebina et al. (2013) used calcium phosphate transfection to deliver plasmid DNA encoding Cas9 and sgRNA into latent HIV-1-infected human 293 T cells.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ebina et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various gene editing technologies have recently been shown to remove the proviral HIV-1 DNA from the host cell genome by targeting its highly conserved 5′ and 3′ long terminal repeats (LTRs)”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the appropriate guide RNA, the Cas9 enzyme can recognize and cleave virtually any viral genome (29).”
From RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection (2014) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Off-target effects refer to the possibility that the CRISPR/Cas9 system may cut DNA at a non-specific location other than the target DNA, resulting in unwanted gene mutations or interference with normal gene function [10].”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, this proof of concept is certainly applicable to any other cell type, including T-lymphoid cells (Fig. S6) (12,13), astrocytes, and neural stem cells”
From RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection (2014) · cites this paper as [12]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Makarova, K. S., Grishin, N. V., Shabalina, S. A., Wolf, Y. I., & Koonin, E. V. (2006) · Biology Direct · doi:10.1186/1745-6150-1-7 · Cited by 1,199
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
Jordan, A., Bisgrove, D., & Verdin, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg188 · Cited by 914
Cited by
Items 301–400 of 562
Gene Therapy Strategies for HIV/AIDS: Preclinical Modeling in Humanized Mice
Bennett, M. S., & Akkina, R. (2013) · Viruses · doi:10.3390/v5123119 · Cited by 20
“One in vitro study involving the CRISPR/Cas9 system demonstrated inhibition of an HIV LTR [100].”
BackgroundConnecting HIV ‐1 integration and transcription: a step toward new treatments
Lucic, B., & Lušić, M. (2016) · FEBS Letters · doi:10.1002/1873-3468.12226 · Cited by 17
Developmental history and application of CRISPR in human disease
Liang, P., Zhang, X., Chen, Y., & Huang, J. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2963 · Cited by 19
Fight fire with fire: Gene therapy strategies to cure HIV
Huyghe, J., Sips, M., & Vandekerckhove, L. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1353911 · Cited by 20
Use of Customizable Nucleases for Gene Editing and Other Novel Applications
Reddy, P., Vilella, F., Belmonte, J. C. I., & Simón, C. (2020) · Genes · doi:10.3390/genes11090976 · Cited by 18
Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system
Yu, M., Liu, X., Cheng, H., Kuang, L., Zhang, S., & Yan, X. (2021) · Methods · doi:10.1016/j.ymeth.2021.06.004 · Cited by 17
Antiviral treatment strategies based on gene silencing and genome editing
Badía, R., Ballana, E., Esté, J. A., & Riveira‐Muñoz, E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.04.001 · Cited by 16
Luteijn, R. D., Drexler, I., Smith, G. L., Lebbink, R. J., & Wiertz, E. J. H. J. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001034 · Cited by 19
Bloom, K. M., Mussolino, C., & Arbuthnot, P. B. (2015) · Current Stem Cell Reports · doi:10.1007/s40778-014-0008-7 · Cited by 16
CRISPR/Cas13-Based Anti-RNA Viral Approaches
Tan, X., Li, J., Cui, B., Wu, J., Toischer, K., Hasenfuss, G. P., & Xu, X. (2025) · Genes · doi:10.3390/genes16080875 · Cited by 22
“…integrated proviral DNA and demonstrated that CRISPR/Cas9 could successfully inhibit HIV-1 genome expression, disrupt viral gene expression, and reduce viral replication in Jurkat cell lines, showing that targeting multiple sites in the genome simultaneously could enhance excision efficiency [61].”
Hawsawi, Y. M., Shams, A. M., Theyab, A., Siddiqui, J., Barnawee, M., Abdali, W. A., Marghalani, N. A., Alshelali, N. H., Al-Sayed, R., Alzahrani, O. R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.869889 · Cited by 20
“Additionally, subsequent studies targeting either HIV gens or LTR sequence of HIV-1 DNA have demonstrated similar suppression results (Ebina et al., 2013; Hu et al., 2014; Christian et al., 2022).”
ResultHIV cure: Are we going to make history?
Payra, S., Manjhi, P. K., Singh, S., Kumar, R., Singh, S. K., Kumar, A., & Maharshi, V. (2023) · HIV Medicine · doi:10.1111/hiv.13557 · Cited by 16
“Other strategies that have also been tried include (but are not limited to) chimeric antigen receptor cell therapeutic and latency breakers with ART (shock and kill method) [59 – 65].”
MethodWang, X., Wang, P., Fu, Z., Ji, H., Qu, X., Zeng, H., Zhu, X., Deng, J., Lu, P., Zha, S., et al. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0121 · Cited by 14
Electronic Structure and Theoretical Aspects on Sensing Application of 2D Materials
Chakraborty, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102577-2.00005-1 · Cited by 14
Linden, N., & Jones, R. B. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.06.001 · Cited by 16
Potential mechanisms for cell-based gene therapy to treat HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980236 · Cited by 16
“Optimization of sequencespecific nuclease systems has been reported, for example, Tre-recombinase, Talens and Crisp-Cas9 systems that could help to eliminate the quiescent HIV-1 reservoir by excising the HIV-1 proviral DNA.”
BackgroundKuruvilla, J., Sasmita, A. O., & Ling, A. P. K. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3521-0 · Cited by 16
New hope and promise with CRISPR-Cas9 technology for the treatment of HIV
Hassan, H. M., Zubair, A., Helal, M. H., Almagharbeh, W. T., & Elmagzoub, R. M. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01613-1 · Cited by 20
“The researchers Ebina et al. (2013) as were successful in lowering the number of HIV-1 genes that were produced in Jurkat cells by focusing on the NF-κB cassettes that were situated in the U3 region and the TAR sequence that was situated in the R region of the LTR (Ebina et al. 2013).”
Unlocking the potential: advancements and applications of gene therapy in severe disorders
Ingle, R. G., Elossaily, G. M., Ansari, M. N., & Makhijani, S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2516697 · Cited by 17
“Alternatively, cells can be enhanced with supplementary characteristics to eradicate cells infected with HIV [123,127–129].”
Jamehdor, S., Pajouhanfar, S., Saba, S., Uzan, G., Teimoori, A., & Naserian, S. (2022) · Cells · doi:10.3390/cells11060999 · Cited by 13
Zubair, A., Sujan, A., Ali, M., & Hussain, S. M. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70121 · Cited by 14
Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases
Rogers, G. L., & Cannon, P. M. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.008 · Cited by 16
The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses
Gilani, U. S., Shaukat, M., Rasheed, A., Shahid, M., Tasneem, F., Arshad, M. I., Rashid, N., & Shahzad, N. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25292 · Cited by 13
Functional analysis of the UL24 protein of suid herpesvirus 1
Ye, C., Chen, J., Cheng, X., Zhou, S., Jiang, S., Xu, J., Zheng, H., Tong, W., Li, G., & Tong, G. (2018) · Virus Genes · doi:10.1007/s11262-018-1619-3 · Cited by 13
Chung, C.-H., Allen, A. G., Atkins, A., Link, R. W., Nonnemacher, M. R., Dampier, W., & Wigdahl, B. L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.593077 · Cited by 18
“…interspaced short palindromic repeats (CRISPR)-Cas9 system has recently been applied to inactivate HIV-1 replication or excise proviral DNA (Ebina et al., 2013; Hu et al., 2014; Zhu et al., 2015; Yin et al., 2016; Kaminski et al., 2016a; Wang et al., 2016a; Kaminski et al., 2016b; Wang et…”
BackgroundInfluentialRecent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review
Bui, L. M., Phùng, H. T. T., Thi, T.-T. H., Singh, V., Maurya, R., Khambhati, K., Wu, C., Uddin, M. J., Trung, D. M., & Chu, D. (2021) · Bioengineered · doi:10.1080/21655979.2021.1987821 · Cited by 17
“[168] Ebina H, Misawa N, Kanemura Y, et al.”
BackgroundMethodA Novel Approach of Antiviral Drugs Targeting Viral Genomes
Hoang, P. T., Luong, Q. X. T., Ayun, R. Q., Lee, Y., Thuỷ, V. T. B., Kim, T. H., & Lee, S. (2022) · Microorganisms · doi:10.3390/microorganisms10081552 · Cited by 18
“discovered that six crRNAs could target 91% of the sequenced coronaviruses, leading to several other studies using Cas13-targeted SARS-CoV-2 and influenza virus, resulting in positive outcomes in vitro and in vivo [68,82,83].”
BackgroundMethodResultPrecise excision of HTLV-1 provirus with a designer-recombinase
Romanos, T. R., Karpinski, J., Millen, S., Beschorner, N., Simon, F., Paszkowski‐Rogacz, M., Lansing, F., Schneider, P. M., Sonntag, J., Hauber, J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.014 · Cited by 15
In vitro modeling of HIV proviral activity in microglia
Campbell, L. A., Richie, C. T., Zhang, Y., Heathward, E. J., Coke, L. M., Park, E. Y., & Harvey, B. K. (2017) · FEBS Journal · doi:10.1111/febs.14293 · Cited by 14
CRISPR genome editing and its medical applications
Mahmoudian‐Sani, M., Farnoosh, G., Mahdavinezhad, A., & Saidijam, M. (2017) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2017.1406823 · Cited by 13
A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System
Bellizzi, A., Ahye, N., Jalagadugula, G. S., & Wollebo, H. S. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09878-7 · Cited by 14
Harnessing the potential of CRISPR-based platforms to advance the field of hospital medicine
McCarthy, M. W. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1761333 · Cited by 13
“Guide RNAs were created and CRISPR nucleases were delivered to the filamentous fungus Thermothelomyces thermophilus on plasmids.”
BackgroundInfluentialBroadly active zinc finger protein-guided transcriptional activation of HIV-1
Scott, T. A., O’Meally, D., Grepo, N., Soemardy, C., Lazar, D. C., Zheng, Y., Weinberg, M. S., Planelles, V., & Morris, K. V. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.018 · Cited by 13
CRISPR-Based Editing Techniques for Genetic Manipulation of Primary T Cells
Kotowski, M., & Sharma, S. (2020) · Methods and Protocols · doi:10.3390/mps3040079 · Cited by 16
Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics
Canli, T. (2015) · Applied & Translational Genomics · doi:10.1016/j.atg.2015.05.002 · Cited by 14
Inhibiting cyprinid herpesvirus-3 replication with CRISPR/Cas9
Zhao, Y., Wang, T., Yu, Z., Wang, H., Liu, B., Wu, C., & Teng, C. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-2020-0 · Cited by 12
Antiviral therapy of persistent viral infection using genome editing
Buchholz, F., & Hauber, J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.09.012 · Cited by 12
The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy
Sanches-da-Silva, G. D. N., Medeiros, L. F. S., & Lima, F. M. (2019) · International Journal of Genomics · doi:10.1155/2019/8458263 · Cited by 17
“The efficiency increased according to the number of infections, and again, this change occurred by means of indels established at the target sites, as observed earlier [54, 61].”
Regulation of Cas9 by viral proteins Tat and Rev for HIV-1 inactivation
Vergara‐Mendoza, M., Gómez-Quiroz, L. E., Miranda-Labra, R. U., Fuentes-Romero, L. L., Romero‐Rodríguez, D. P., González-Ruíz, J., Hernández-Rizo, S., & Viveros-Rogel, M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104856 · Cited by 16
Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication
Khanal, S., Cao, D., Zhang, J., Zhang, Y., Schank, M., Dang, X., Nguyen, L. N. T., Wu, X. Y., Jiang, Y., Ning, S., et al. (2022) · Viruses · doi:10.3390/v14091902 · Cited by 14
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors
Perdigão, P. R. L., Gaj, T., Santa‐Marta, M., Barbas, C. F., & Gonçalves, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150037 · Cited by 12
Achieving HIV-1 Control through RNA-Directed Gene Regulation
Klemm, V., Mitchell, J., Cortez‐Jugo, C., Cavalieri, F., Symonds, G. P., Caruso, F., Kelleher, A. D., & Ahlenstiel, C. (2016) · Genes · doi:10.3390/genes7120119 · Cited by 11
“There have been several studies that have reported the CRISPR-Cas9 system is efficient at excising certain regions of the provirus, which effectively disables the remaining provirus [89,90].”
BackgroundLü, P., Pan, P., Chen, J., Yu, X., Wu, J., & Chen, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9157 · Cited by 12
An introduction to genome editing CRISPR-Cas systems
Singh, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00001-5 · Cited by 18
Liu, Y., Jeeninga, R. E., Klaver, B., Berkhout, B., & Das, A. T. (2021) · Viruses · doi:10.3390/v13122461 · Cited by 13
Clinical Applications of Genome Editing to HIV Cure
Wang, C. X., & Cannon, P. M. (2016) · AIDS Patient Care and STDs · doi:10.1089/apc.2016.0233 · Cited by 13
Liu, Y., Xu, Y., Wu, P., et al. (2024) · Insect Science · doi:10.1111/1744-7917.13462 · Cited by 10
“CRISPR/Cas9 technology has found widespread applications in virology for gene recombination, immune diagnosis, and the treatment of diverse viruses (Ebina et al. , 2013; Liao et al. , 2015; Wang et al. , 2016; Hille et al. , 2018).”
Borrajo, A. (2025) · Life · doi:10.3390/life15020276 · Cited by 26
“Notably, the study provided evidence that CRISPR/Cas9 could eliminate integrated viral sequences from host cell genomes, highlighting its potential as a novel therapeutic strategy against HIV-1 [67].”
Progression and application of CRISPR-Cas genomic editors
Yang, L., Tang, J., Ma, X., Lin, Y., Ma, G., Shan, M., Wang, L., & Yang, Y. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.013 · Cited by 10
Xu, Y., Zhang, X., Liu, Y., Yang, D., Liu, Z., Chen, K., Tang, L., Wang, M., Hú, Z., Zhang, S., et al. (2021) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2021.103672 · Cited by 10
Zhang, Y., Li, W., Tang, N., Moffat, K., Nair, V., & Yao, Y. (2022) · Journal of Virology · doi:10.1128/jvi.02027-21 · Cited by 10
Basalova, N. A., Illarionova, M. E., Никитична, С. М., Vigovskiy, M. A., Tolstoluzhinskaya, A., Primak, A. L., Сергеевна, Ч. Е., Chechekhin, V. I., Karagyaur, M. N., & Efimenko, A. Y. (2023) · Non-Coding RNA · doi:10.3390/ncrna9050049 · Cited by 10
“At the same time, according to the literature, this CRISPR/Cas9 modification ensures the excision of target DNA fragments in a range of cell lines (e.g., HEK-293T, HeLa, U2OS, murine embryonic stem cells) with high efficiency [16–18], which was also confirmed by our own data in the HEK-293T cell line.”
BackgroundLi, K., Liu, Y., Xu, Z., Zhang, Y., Yao, Y., Nair, V., Liu, C., Zhang, Y., Gao, Y., Qi, X., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.009 · Cited by 11
CRISPR: a journey of gene-editing based medicine
Golkar, Z. (2020) · Genes & Genomics · doi:10.1007/s13258-020-01002-x · Cited by 13
Kim, V., Mears, B. M., Powell, B. H., & Witwer, K. W. (2017) · Matters · doi:10.19185/matters.201611000027 · Cited by 12
“48 h after a Cas9-VP160 fusion protein/gRNA dual expression plasmid (Addgene #48240) was electroporated into the U1 promonocytic line, two HIV-1 gRNAs, previously described and designated T5 and T6 [1], were associated separately with a significant increase in HIV-1 p24 release (by a mean 4.”
MethodInfluentialCRISPR/Cas9 in allergic and immunologic diseases
Goodman, M., Manesh, D. M., Malik, P., & Rothenberg, M. E. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1241711 · Cited by 11
Gene Editing for Treatment of Neurological Infections
White, M. K., Kaminski, R., Wollebo, H. S., Hu, W., Malcolm, T., & Khalili, K. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0439-1 · Cited by 9
“The CRISPR/Cas9 system has been used to target the HIV-1 long terminal repeat (LTR) of integrated proviral DNA in the genome of cells in tissue culture [36, 40].”
Targeting and Understanding HIV Latency: The CRISPR System against the Provirus
Magro, G., Calistri, A., & Parolin, C. (2021) · Pathogens · doi:10.3390/pathogens10101257 · Cited by 10
“The first proof-of-principle that CRISPR-Cas9 could be exploited to treat HIV infection, at least in vitro, was reported in 2013 [46], just one year after the discovery of the CRISPR-Cas9 system as a programmable genome editing tool [24].”
BackgroundSo Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research
Kleinman, A. J., Pandrea, I., & Apetrei, C. (2022) · Viruses · doi:10.3390/v14010135 · Cited by 11
Toll-interacting protein inhibits HIV-1 infection and regulates viral latency
Li, C., Kuang, W.-D., Qu, D., & Wang, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.05.065 · Cited by 9
Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era
Weatherley, D. A. V., Boswell, M. T., & Rowland‐Jones, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01616 · Cited by 12
“org November 2017 | Volume 8 | Article 1616 both transcriptionally active and latent virus by targeting the HIV-1 long-terminal repeat (LTR), which caps both ends of the integrated proviral genome has also been reported but is limited by the clustering of escape mutations at the Cas9 cleavage site (52, 53).”
BackgroundCRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures
Fan, M., Bao, Y., Berkhout, B., & Herrera-Carrillo, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115046 · Cited by 8
CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects
Kaligotla, V. S. A., Jasti, T., & Kandra, P. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2200 · Cited by 9
Interventions during Early Infection: Opening a Window for an HIV Cure?
Hiner, C. R., Mueller, A. L., Su, H., & Goldstein, H. (2024) · Viruses · doi:10.3390/v16101588 · Cited by 10
“Several studies show that infected cells targeted for editing resulted in significant suppression of virus production [261–265].”
BackgroundTargeting HIV-1 proviral transcription
Olson, A., Basukala, B., Wong, W. W., & Henderson, A. J. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.07.011 · Cited by 9
CRISPR/Cas9 System and its Research Progress in Gene Therapy
Liu, W., Yang, C., Liu, Y., & Jiang, G. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191014103711 · Cited by 8
Murphy, B. G., Wolf, T., Vogel, H., Castillo, D., & Woolard, K. (2020) · Viruses · doi:10.3390/v12050511 · Cited by 29
“In HIV infected human patients on antiretroviral Viruses 2020, 12, 511 12 of 14 therapy, the number of latently infected peripheral CD4+ T cells ranges from 1 to 10 cells per 106 [28].”
MethodInfluentialEradication of Human Immunodeficiency Virus Type-1 (HIV-1)-Infected Cells
Düzgüneş, N., & Konopka, K. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11060255 · Cited by 7
“Upon stimulation of the cells, LTR-driven gene expression was inhibited significantly [49].”
BackgroundWill CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications
Senthilathiban, D. P., Kuduvalli, S. S., & Anitha, T. S. (2021) · Molecular Biotechnology · doi:10.1007/s12033-020-00289-1 · Cited by 9
Xu, Y., Peng, X., Zheng, Y., Jin, C., Lu, X., Han, D., Fu, H., Chen, C., & Wu, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.629153 · Cited by 10
Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells
Cheng, Y., Chen, G., Yang, X. P., Wang, Y., & Li, H. (2018) · Current Medical Science · doi:10.1007/s11596-018-1868-3 · Cited by 7
Chin, W.-X., Ang, S. K., & Chu, J. J. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.008 · Cited by 9
Exploring the evolutionary links: Innate immunity in bacteria and eukaryotes
Abavisani, M., Faraji, S., Ansari, B., Ebadpour, N., Kesharwani, P., & Sahebkar, A. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.08.023 · Cited by 8
CRISPR/CAS as a Powerful Tool for Human Immunodeficiency Virus Cure: A Review
Komninakis, S. V., Domingues, W., Sanabani, S. S., Folgosi, V. Â., Barbosa, I. N., & Casseb, J. (2024) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0148 · Cited by 7
“60 TAT protein, a transcriptional transactivator, is detected in the cerebrospinal fluid of HIV-positive patients on cART with undetectable viral load in plasma at levels that vary over time.”
RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens
Kola, N. S., Patel, D., & Thakur, A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3890-3_21 · Cited by 7
CRISPR therapy: A revolutionary breakthrough in genetic medicine
Barreto, G. D. S., do Nascimento, J. B., de Almeida, K. C. S., Neto, J. C. M., & da Silva, S. L. F. L. (2024) · International Healthcare Review (online) · doi:10.56226/88 · Cited by 7
Sui, C., Wan, H., Han, W., Zhou, L., & Wang, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220307104501 · Cited by 6
Salampe, M., Mamada, S. S., Evary, Y. M., Mitra, S., Emran, T. B., Harapan, H., Nainu, F., & Simal‐Gándara, J. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220831114838 · Cited by 7
Suwito, B. E., Adji, A. S., Wardani, V. A. K., Widjaja, J. S., Angel, S. C. S., & Rahman, F. S. (2022) · Bali Medical Journal · doi:10.15562/bmj.v11i2.3414 · Cited by 6
Computational analysis of cas proteins unlocks new potential in HIV-1 targeted gene therapy
Dampier, W., Berman, R. E., Nonnemacher, M. R., & Wigdahl, B. L. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1248982 · Cited by 6
Current Progress and Future Prospects in Nucleic Acid Based Therapeutics
Takahashi, M. M., Han, S., Scherer, L. J., Yoon, S., & Rossi, J. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12424-2 · Cited by 8
Wahid, B., Usman, S., Ali, A., Saleem, K., Rafique, S., Naz, Z., Ashfaq, H. A., & Idrees, M. (2017) · Viral Immunology · doi:10.1089/vim.2017.0055 · Cited by 7
Protein Delivery of Cell-Penetrating Zinc-Finger Activators Stimulates Latent HIV-1-Infected Cells
Perdigão, P. R. L., Cunha-Santos, C., Barbas, C. F., Santa‐Marta, M., & Gonçalves, J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.016 · Cited by 8
The potential use of Drosophila as an in vivo model organism for COVID-19-related research: a review
Demir, E. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2104-26 · Cited by 8
“The potential of CRISPR-Cas9 gene-editing system as a promising tool in treating and preventing HIV infection was shown in early research (Ebina et al., 2013).”
BackgroundAn introduction to advanced technologies in synthetic biology
Singh, V., Bhattacharjee, G., Gohil, N., Maurya, R., Lam, N. L., & Alzahrani, K. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824469-2.00021-x · Cited by 9
Type I-E CRISPR-Cas System as a Defense System in Saccharomyces cerevisiae
Rath, D., Amlinger, L., Bindal, G., & Lundgren, M. (2022) · mSphere · doi:10.1128/msphere.00038-22 · Cited by 6
[Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].
Han, Y., & Li, Q. (2016) · Hereditas (Beijing) · doi:10.16288/j.yczz.15-284 · Cited by 7
CRISPR Technology: Transforming the Future of Medicine and Diagnostics
Iyer, K. A., Tenchov, R., Diaz, L. M. L., Jain, P., Thite, T., Deng, Y., & Zhou, Q. A. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00480 · Cited by 13
Next-generation gene therapy for infectious disease: Advances, challenges, and future directions
Fattahi, M., Pirbadami, F., Motallebirad, T., Beheshti, Z., & Azadi, D. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103164 · Cited by 5
Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox
Wang, W., Gao, Q., Li, Y., Guo, H., Zheng, J., Fu, Y., & Liao, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03876-z · Cited by 9
“The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system, a core component of microbial adaptive immunity, utilizes CRISPR-associated (Cas) endonucleases (like Cas12a and Cas13a) to recognize and cleave foreign nucleic acids with high sequence specificity [70].”
A New World Order: Tailored Gene Targeting and Regulation Using CRISPR
Weinberg, M. S., & Morris, K. V. (2014) · Molecular Therapy · doi:10.1038/mt.2014.54 · Cited by 5
CRISPR/Cas9-mediated genome editing: from basic research to gene therapy
Goel, R. (2024) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20241589 · Cited by 8
Nicholson, S., Moyo, B., & Arbuthnot, P. B. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i6.859 · Cited by 5
Application of CRISPR-Cas9 Technology in Fish
Aich, N., Parhi, J., Mandal, S. C., & Sahoo, L. (2023) · Springer eBooks · doi:10.1007/978-981-99-2981-8_2 · Cited by 10
Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs
Peterson, T. A., & MacLean, A. G. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9814-5 · Cited by 7
A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness
Yoder, K. E. (2019) · Acta Virologica · doi:10.4149/av_2019_201 · Cited by 5
“Genome editing technologies have been proposed as one strategy for a cure by deleting or disabling the latent HIV-1 provirus (Aubert et al., 2011; Ebina et al., 2013; Hu et al., 2014; Liao et al., 2015; Qu et al., 2013; Zhu et al., 2015).”
BackgroundMethodInfluentialZhang, C., Li, H., Poluektova, L. Y., Gendelman, H. E., & Dash, P. K. (2025) · Communications Biology · doi:10.1038/s42003-025-08499-6 · Cited by 5
Recent advances in CRISPR/Cas9-assisted gene therapy
Srivastava, A., Chauhan, S., & Ahuja, V. (2023) · Karbala International Journal of Modern Science · doi:10.33640/2405-609x.3330 · Cited by 6
“It successfully disrupts the expression of active HIV-1 provirus but prevents latent infection [67].”
BackgroundSiles, L., & Pomares, E. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102482 · Cited by 4
“27,28 Also other genetic disorders, including cancer, 29 – 31 Duchenne muscular dystrophy 32 or viral infections, 33 – 35 are taking advantage of genome editing as a therapeutic strategy.”
What's in a cure: designing a broad-spectrum HIV gene therapy
Berman, R. E., Dampier, W., Nonnemacher, M. R., & Wigdahl, B. L. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000846 · Cited by 4
Metadata
- Authors
- Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
- Affiliations
- Kyoto University (JP)
- Corresponding author
- Ebina, Hirotaka
- Venue
- Scientific Reports
- Published
- 2013-08-26
- Volume
- 3
- Issue
- 1
- Pages
- 2510-2510
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3752613
- OpenAlex
- W1966452674
- Cited by
- 565
- References
- 28
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24115008)
- Japan Society for the Promotion of Science (24790438, 24390112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
- MeSH terms
- HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.